FDA-APPROVED PATIENT LABELING COULD REPLACE BRIEF SUMMARY FOR DIRECT-TO-CONSUMER ADS; AGENCY ADVISING INDUSTRY TO FOLLOW CURRENT DTC REGS FOR INTERNET SITES
Approved patient labeling could substitute for the brief summary required by direct-to-consumer advertising, the agency suggests in a request for comments on direct-to-consumer promotions issued May 14.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth